Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 334

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 334
---
 meeting of stockholders to a later date.

On August 16, 2024, the parties to the Business Combination Agreement amended the Business Combination Agreement to extend the Outside Date to December 31, 2024. Also on August 16, 2024, the parties to the PIPE Equity Subscription Agreement entered into an amendment to such agreement to extend the termination date of the agreement to December 31, 2024.

On August 26, 2024, the Company filed a proxy statement with the SEC containing a proposal to stockholders to amend the Iris Certificate of Incorporation to extend the date by which the Company must consummate a business combination from September 9, 2024 to December 31, 2024. The Company’s stockholders approved the amendments to the Iris Certificate of Incorporation at the special meeting on September 5, 2024. On September 5, 2024, the Company filed with the Secretary of State of the State of Delaware an amendment to its amended and restated certificate of incorporation to change the date by which the Company must consummate a business combination to December 31, 2024. Additionally, on September 5, 2024, stockholders holding 48,107 shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $11.17 per share, subject to adjustment for applicable taxes, including, but not limited to, franchise tax, excise tax and income tax. Following such redemptions, 238,930 shares of Iris Class A Common Stock remained outstanding.

On October 23, 2024, the parties to the Business Combination Agreement amended the Business Combination Agreement to, among other things, reduce the enterprise value associated with Liminatus to

<div align='center'>179</div>

TABLE OF CONTENTS

$175 million. On October 31, 2024, the parties to the PIPE Equity Subscription Agreement entered into an amendment to such agreement to reduce the PIPE Investor’s committed purchase of PIPE Shares from 2,500,000 to 1,500,000, and decrease the PIPE Equity Investment from $25 million to $15 million.

On December 9, 2024, Iris filed a proxy statement with the SEC containing a proposal to stockholders to amend the Iris Certificate of Incorporation to extend the date by which Iris must consummate a business combination from December 31, 2024 to March 31, 2025 (subject to an additional three month extension at the discretion of